rare-diseases-2016_scientifictracks-workshop

30 / 30

Page 45
Notes:
conferenceseries.com
October 26-27, 2016 Chicago, USA
Annual Congress on
Rare Diseases & Orphan Drugs
Volume 7, Issue 5 (Suppl) J Genet Syndr Gene Ther
ISSN: 2157-7412 JGSGT, an open access journal Rare Diseases 2016
October 26-27, 2016
Pricing, public health, & politics: Policy considerations for orphan products
Anne Marie Finley
Biotech Policy Group LLC, USA
Drug prices in the United States are higher than anywhere else in the world. Orphan products have long been perceived as pricier
than many other drugs by payers, manufacturers and consumers. The Affordable Care Act’s expansion of insurance coverage
and pharmaceutical benefits, along with a growing resistance to higher priced therapies, have added to the pharmaceutical pricing
stress on the healthcare system and ultimately rare disease patients. Innovative responses to the current pharmaceutical pricing crisis
have been developed by some drug companies, patient organizations, payers, regulators and legislators. The new Congress and new
Administration have a number of options and opportunities by which to address pricing concerns in 2017.
Biography
Anne Marie Finley is the FDA Regulatory and Health Care Policy Strategist. She is the President of Biotech Policy Group, a consulting firm she founded in 2001
that focuses on development of products for rare diseases and unmet medical needs. She has more than 25 years’ experience in senior management positions at
the Food and Drug Administration, US Department of Health and Human Services, the US Congress. She was named a top 50 Thought Leader in Orphan Drugs
and Rare Diseases in 2014.
Anne Marie Finley, J Genet Syndr Gene Ther 2016, 7:5 (Suppl)